In a 50-year-old woman with a history of peptic ulcer disease, systemic lupus erythematosus, and ulcerative colitis, presenting with severe Clostridioides difficile colitis (fever, hypotension, leukocytosis, thrombocytosis, rising creatinine, and colonic dilation without perforation) despite oral vancomycin, should the next step be intravenous metronidazole, escalation of oral vancomycin, fidaxomicin, or surgical intervention?

{
  "question": "A [AGE]-year-old woman evaluated for diarrhea and abdominal pain. She recently completed treatment for H. pylori gastritis. Past medical history is significant for peptic ulcer disease, SLE, and C. diff colitis that occurred a year ago. Current medications include pantoprazole, [MEDICATION], hydroxychloroquine, and vitamin D. Temperature [TEMPERATURE], pulse [VITAL_SIGN], blood pressure [VITAL_SIGN]. WBC count [LAB_VALUE], platelet count [LAB_VALUE], creatinine [LAB_VALUE]. Stool test positive for C. diff. GFR [LAB_VALUE]. She was started on IV fluids and oral vancomycin. She continues to have low blood pressures on day 3, with [NUMBER] episodes of diarrhea and mucus-like stools. Increasing abdominal pain and distention with decreased bowel sounds. Repeat labs on day 3: hemoglobin [LAB_VALUE], WBC [LAB_VALUE], BUN [LAB_VALUE], creatinine [LAB_VALUE], GFR [LAB_VALUE]. CT shows dilation and inflammation of colon, no evidence of perforation. Oral vancomycin increased to 500 mg by mouth every 6 hours. Surgery consultation requested. Which of the following should you do: a) intravenous metronidazole, b) emergency fecal transplant, c) oral rifampin, d) fidaxomicin?"
}

---

Fulminant C. difficile Colitis: Add IV Metronidazole and Prepare for Surgery

This patient has fulminant Clostridioides difficile infection (CDI) and requires immediate addition of intravenous metronidazole 500 mg every 8 hours to the high-dose oral vancomycin regimen already in place, with urgent surgical consultation for potential colectomy.

Clinical Recognition of Fulminant CDI

This case demonstrates classic fulminant CDI criteria 1:

• Hypotension (persistent low blood pressure despite fluids)
• Marked leukocytosis (WBC 21,000 on day 3, rising from 16,200)
• Rising creatinine (2.1, up from 1.7) with declining GFR (28, down from 36)
• Colonic dilation and inflammation on CT imaging
• Clinical deterioration despite oral vancomycin (worsening symptoms, decreased bowel sounds suggesting ileus)

The combination of hemodynamic instability, rising WBC ≥20,000, worsening renal function, and colonic dilation without perforation defines this as fulminant disease requiring escalated medical therapy and surgical readiness 1, 2.

Immediate Medical Management

Add IV Metronidazole Now

The standard of care for fulminant CDI is high-dose oral vancomycin (500 mg every 6 hours—already appropriately escalated in this patient) PLUS intravenous metronidazole 500 mg every 8 hours 1, 3. The 2018 IDSA/SHEA guidelines provide strong recommendation with moderate quality evidence for this combination 1.

Why add IV metronidazole?

• When ileus develops (suggested here by decreased bowel sounds and distention), oral vancomycin delivery to the colon becomes impaired 1, 2
• IV metronidazole achieves therapeutic concentrations in inflamed colonic tissue even when oral delivery fails 1
• The combination addresses both local (vancomycin) and systemic (metronidazole) aspects of severe infection 1, 2

Consider Rectal Vancomycin

If ileus worsens, rectal vancomycin 500 mg in 100 mL normal saline every 6 hours as retention enema should be added 1. This provides direct colonic delivery when oral administration is compromised, though evidence is weaker (weak recommendation, low quality) 1.

Why Not the Other Options?

Fidaxomicin (Option D): Wrong Timing

Fidaxomicin is not recommended for fulminant CDI 1, 3. While fidaxomicin is preferred over vancomycin for initial non-severe CDI and recurrent CDI due to lower recurrence rates 1, 4, it has:

• No data supporting use in fulminant disease 1
• The 2018 IDSA/SHEA guidelines explicitly recommend vancomycin (not fidaxomicin) for fulminant CDI 1
• This patient is already on appropriately escalated vancomycin—switching would delay proven therapy

Emergency Fecal Transplant (Option B): Wrong Indication

Fecal microbiota transplantation (FMT) is indicated for recurrent CDI (≥2 recurrences), not acute fulminant disease 1, 3, 5. The 2021 IDSA/SHEA update recommends FMT after at least 2 recurrences (i.e., third CDI episode) 3.

• This patient had CDI one year ago but this appears to be a new episode, not a recurrence
• FMT has no role in acute fulminant management 1, 5
• Even in IBD patients with CDI (this patient has ulcerative colitis history), FMT is reserved for recurrent disease 5, 6

Oral Rifampin (Option C): No Evidence

Rifaximin (not rifampin) has been studied only as adjunctive therapy following vancomycin for recurrent CDI (vancomycin 125 mg QID × 10 days, then rifaximin 400 mg TID × 20 days) 1. There is:

• No evidence for rifaximin in fulminant CDI 1
• Concern for resistance development 1
• No role in acute management of severe disease

Surgical Considerations: Prepare for Colectomy

Surgery consultation is already appropriately requested. Indications for urgent colectomy in fulminant CDI include 1, 2:

High-Risk Features Present in This Patient:

• Rising WBC ≥20,000 (now 21,000)—associated with high mortality 1
• Worsening lactate (if measured and ≥5 mmol/L, strongly predicts need for surgery) 2
• Clinical deterioration despite appropriate antibiotics
• Hemodynamic instability (persistent hypotension)

Surgical Options:

1. Subtotal colectomy with preservation of rectum (traditional approach—strong recommendation, moderate evidence) 1, 2

2. Diverting loop ileostomy with colonic lavage followed by antegrade vancomycin flushes (alternative that may improve outcomes—weak recommendation, low evidence) 1, 7, 8

Timing is critical: Surgery should be performed before colitis becomes very severe—ideally before lactate exceeds 5.0 mmol/L 2. Delayed surgery while continuing ineffective medical therapy increases morbidity and mortality 9.

Special Consideration: IBD and CDI

This patient has ulcerative colitis (UC) and SLE, creating additional complexity 5, 10, 6:

• Continue IBD therapy (hydroxychloroquine, pantoprazole) during CDI treatment—do not stop immunosuppression 5
• Higher recurrence risk in IBD patients (17.4% with metronidazole, 8.2% with vancomycin) 10
• If this becomes recurrent CDI, consider bezlotoxumab (monoclonal antibody against toxin B) as adjunctive therapy 7, 5
• Endoscopy may be needed if symptoms persist 48-72 hours after treatment initiation to assess IBD activity and exclude CMV co-infection 5

Common Pitfalls to Avoid

1. Delaying IV metronidazole in fulminant disease—add it immediately when hypotension, high WBC, or ileus develop 1

2. Using metronidazole alone—it is inferior to vancomycin and should only be added to (not substituted for) vancomycin in fulminant CDI 1, 3

3. Waiting too long for surgery—early surgical consultation and intervention before severe deterioration improves survival 1, 2, 9

4. Stopping immunosuppression in IBD patients with CDI—continue IBD therapy while treating infection 5

5. Using antiperistaltic agents (loperamide, opiates)—these are contraindicated in severe CDI and can precipitate toxic megacolon 2

Monitoring and Next Steps

• Serial WBC and lactate every 12-24 hours—rising values predict surgical need 1, 2
• Hemodynamic monitoring—persistent shock despite resuscitation indicates surgery 1, 2
• Daily surgical reassessment—do not delay colectomy if medical therapy fails within 48-72 hours 1, 9
• Consider vancomycin levels if renal failure worsens—high-dose oral vancomycin can achieve systemic absorption in severe colitis 11

The answer is (a): Add intravenous metronidazole 500 mg every 8 hours immediately, continue high-dose oral vancomycin, and prepare for potential urgent colectomy if no improvement within 24-48 hours 1, 3.